Haddad David Alan
Known title: DirectorCIK: 0002140040
Associated companies
Transaction History
| TTD | ▲ Buy | Grant | 13,193 | $0 | 6/11/2026 | View on chart |
| TTD | ▲ Buy | Grant | 11,820 | $0 | 6/11/2026 | View on chart |
| TTD | ▲ Buy | Grant | 13,193 | $0 | 6/11/2026 | View on chart |
| TTD | ▲ Buy | Grant | 11,820 | $0 | 6/11/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
TTD down 77% while market rises; healthcare integration news
The Trade Desk shares have fallen 77% while the broader market has risen, leading to comparisons with other ad-tech stocks like Alphabet and AppLovin. Recent news highlights a healthcare inventory integration with OptimizeRx, which may be relevant to its advertising capabilities. Despite the significant price drop, the stock trades at a trailing P/E of 13.8, well below its 52-week high of $56.39.
TTD down 77% while market rises; healthcare integration news. The Trade Desk shares have fallen 77% while the broader market has risen, leading to comparisons with other ad-tech stocks like Alphabet and AppLovin. Recent news highlights a healthcare inventory integration with OptimizeRx, which may be relevant to its advertising capabilities. Despite the significant price drop, the stock trades at a trailing P/E of 13.8, well below its 52-week high of $56.39.